In vitro activity of ceftazidime-avibactam and comparators against contemporary carbapenem resistant Gram-negative clinical isolates

• Grant number: 23/10558-0
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: November 01, 2023
• End date: February 29, 2024
• Field of knowledge: Biological Sciences - Microbiology - Applied Microbiology
• Principal Investigator: Carlos Henrique Camargo
• Grantee: Cristiane Ribeiro Menezes da Silva
• Host Institution: Instituto Adolfo Lutz (IAL). Coordenadoria de Controle de Doenças (CCD). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil

Abstract

The aim of this investigation is to evaluate the presence of Gram-negative isolates with resistance to ceftazidime-avibactam, a new antimicrobial introduced on the Brazilian market in 2018, in clinical isolates from patients with healthcare-associated infections. To this end, 100 isolates received at our reference laboratory (Center for Bacteriology, Adolfo Lutz Institute) will be evaluated during the years 2021 to 2023.We will initially identify the isolates by molecular methods, and then evaluate their susceptibility through the broth microdilution method and to compare the results with Etest and disk-diffusion.. Resistant samples will be submitted to susceptibility tests for other antimicrobials, in order to characterize their complete resistance profile.Resistant isolates will have the blaKPC gene sequenced. The data generated is extremely important because sensitivity monitoring is essential to preserve the activity of new therapeutic options, and the great differential of this proposal is the possibility of including isolates from different hospitals in our coverage area.